A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts

Maiko Matsushita, Yoshie Ozaki, Yuka Hasegawa, Fukiko Terada, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, Tsukasa Oikawa, Koichi Matsuo, Wenlin Du, Taketo Yamada, Masashi Hozumi, Daijyu Ichikawa, Yutaka Hattori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

January Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma-bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the Cmax was 2.1 μM at 1 h after the injection of TC11, with 1.2 h as the half-life. TC11 significantly inhibited the differentiation and function of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts in mouse osteoclast cultures using M-CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by α-tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high-risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.

Original languageEnglish
Article numbere0116135
JournalPLoS One
Volume10
Issue number1
DOIs
Publication statusPublished - 2015 Jan 24

Fingerprint

phthalimide
myeloma
osteoclasts
Osteoclasts
Multiple Myeloma
Pharmacokinetics
chemical derivatives
Derivatives
Bearings (structural)
Apoptosis
Thalidomide
Macrophage Colony-Stimulating Factor
Molecular interactions
cells
Tubulin
Chromosomes
Acid Phosphatase
Pharmaceutical Preparations
Tumors
Bone

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. / Matsushita, Maiko; Ozaki, Yoshie; Hasegawa, Yuka; Terada, Fukiko; Tabata, Noriko; Shiheido, Hirokazu; Yanagawa, Hiroshi; Oikawa, Tsukasa; Matsuo, Koichi; Du, Wenlin; Yamada, Taketo; Hozumi, Masashi; Ichikawa, Daijyu; Hattori, Yutaka.

In: PLoS One, Vol. 10, No. 1, e0116135, 24.01.2015.

Research output: Contribution to journalArticle

Matsushita, M, Ozaki, Y, Hasegawa, Y, Terada, F, Tabata, N, Shiheido, H, Yanagawa, H, Oikawa, T, Matsuo, K, Du, W, Yamada, T, Hozumi, M, Ichikawa, D & Hattori, Y 2015, 'A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts', PLoS One, vol. 10, no. 1, e0116135. https://doi.org/10.1371/journal.pone.0116135
Matsushita, Maiko ; Ozaki, Yoshie ; Hasegawa, Yuka ; Terada, Fukiko ; Tabata, Noriko ; Shiheido, Hirokazu ; Yanagawa, Hiroshi ; Oikawa, Tsukasa ; Matsuo, Koichi ; Du, Wenlin ; Yamada, Taketo ; Hozumi, Masashi ; Ichikawa, Daijyu ; Hattori, Yutaka. / A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. In: PLoS One. 2015 ; Vol. 10, No. 1.
@article{bc605d82a7764afa9283e560e27ef931,
title = "A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts",
abstract = "January Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma-bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the Cmax was 2.1 μM at 1 h after the injection of TC11, with 1.2 h as the half-life. TC11 significantly inhibited the differentiation and function of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts in mouse osteoclast cultures using M-CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by α-tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high-risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.",
author = "Maiko Matsushita and Yoshie Ozaki and Yuka Hasegawa and Fukiko Terada and Noriko Tabata and Hirokazu Shiheido and Hiroshi Yanagawa and Tsukasa Oikawa and Koichi Matsuo and Wenlin Du and Taketo Yamada and Masashi Hozumi and Daijyu Ichikawa and Yutaka Hattori",
year = "2015",
month = "1",
day = "24",
doi = "10.1371/journal.pone.0116135",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts

AU - Matsushita, Maiko

AU - Ozaki, Yoshie

AU - Hasegawa, Yuka

AU - Terada, Fukiko

AU - Tabata, Noriko

AU - Shiheido, Hirokazu

AU - Yanagawa, Hiroshi

AU - Oikawa, Tsukasa

AU - Matsuo, Koichi

AU - Du, Wenlin

AU - Yamada, Taketo

AU - Hozumi, Masashi

AU - Ichikawa, Daijyu

AU - Hattori, Yutaka

PY - 2015/1/24

Y1 - 2015/1/24

N2 - January Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma-bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the Cmax was 2.1 μM at 1 h after the injection of TC11, with 1.2 h as the half-life. TC11 significantly inhibited the differentiation and function of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts in mouse osteoclast cultures using M-CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by α-tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high-risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.

AB - January Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma-bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the Cmax was 2.1 μM at 1 h after the injection of TC11, with 1.2 h as the half-life. TC11 significantly inhibited the differentiation and function of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts in mouse osteoclast cultures using M-CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by α-tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high-risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.

UR - http://www.scopus.com/inward/record.url?scp=84921909025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921909025&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0116135

DO - 10.1371/journal.pone.0116135

M3 - Article

C2 - 25617756

AN - SCOPUS:84921909025

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0116135

ER -